Market Place
Sourcing Support
New Bladder Cancer Treatment Enters FDA Review Process
15 Jan 2025 //
PR NEWSWIRE
J&J doubles down on neurological drugs with $14.6 billion deal
14 Jan 2025 //
REUTERS
J&J explores bid for Intra-Cellular Therapies, reports
13 Jan 2025 //
REUTERS
Nipocalimab granted FDA Review for Myasthenia gravis
10 Jan 2025 //
PR NEWSWIRE
J&J pauses Varipulse US debut following 4 reports of strokes
08 Jan 2025 //
FIERCE BIOTECH
J & J Posdinemab and Tau Active Receive FDA Fast Track Designations
08 Jan 2025 //
PR NEWSWIRE
J&J`s combo extend patient` lives in study with AstraZeneca`s drug
08 Jan 2025 //
FIERCE PHARMA
Johnson & Johnson Announces Quarterly Dividend for Q1 2025
02 Jan 2025 //
BUSINESSWIRE
EU clears J&J`s Rybrevant,Lazcluze duo for first-line lung cancer
31 Dec 2024 //
PRESS RELEASE
Kaken, J&J ink potential $1.2B-plus STAT6 deal
28 Dec 2024 //
PRESS RELEASE
Johnson & Johnson Seeks EMA Approval for IMBRUVICA® in MCL
18 Dec 2024 //
GLOBENEWSWIRE
FDA declines to approve injection form of J&J`s lung cancer drug
17 Dec 2024 //
REUTERS
Johnson & Johnson To Join 43rd J.P. Morgan Healthcare Conference
12 Dec 2024 //
BUSINESSWIRE
ICER calls out drugmakers over `unsupported` price hikes
12 Dec 2024 //
REUTERS
LAVA Reports Q3 2024 Financial Results
10 Dec 2024 //
GLOBENEWSWIRE
J&J to Host Investor Conference Call on Fourth-Quarter Results
10 Dec 2024 //
BUSINESSWIRE
Citryll Raises EUR 85 Million for NET-Targeting Therapy
09 Dec 2024 //
GLOBENEWSWIRE
CARVYKTI® Shows Higher MRD Negativity in CARTITUDE-4 Study
09 Dec 2024 //
PR NEWSWIRE
DARZALEX FASPRO® Improves MRD Negativity in Multiple Myeloma
08 Dec 2024 //
PR NEWSWIRE
Darzalex Faspro Reduces Risk In Smoldering Multiple Myeloma
08 Dec 2024 //
PR NEWSWIRE
Tecayli Shows Potential as Frontline Therapy in Multiple Myeloma
08 Dec 2024 //
PR NEWSWIRE
J&J looks to expand Tremfya in two pediatric indications
03 Dec 2024 //
PR NEWSWIRE
J & J seeks approval for first pediatric indications for Tremfya
02 Dec 2024 //
PR NEWSWIRE
J&J Seeks FDA Approval for TREMFYA® in Ulcerative Colitis
22 Nov 2024 //
PR NEWSWIRE
UK talc claimants set to file suit in class action vs. J&J
22 Nov 2024 //
FIERCE PHARMA
Biolojic Design Joins Johnson & Johnson Innovation - JLABS
19 Nov 2024 //
GLOBENEWSWIRE
Johnson & Johnson Showcases Hematology Portfolio at ASH 2024
19 Nov 2024 //
PR NEWSWIRE
J&J`s oral skin disease drug meets main goals of late-stage study
19 Nov 2024 //
REUTERS
New IL-23 UC drugs `rapidly gained significant momentum`: report
18 Nov 2024 //
FIERCE PHARMA
Biotechs behind J&J-bought Yellow Jersey partner on IBD drug
15 Nov 2024 //
FIERCE BIOTECH
EU regulators endorse meds from BMS, J&J, Eisai and more
15 Nov 2024 //
FIERCE PHARMA
CHMP Recommends Rybrevant & Lazcluze® for EGFR-mutant NSCLC
15 Nov 2024 //
GLOBENEWSWIRE
GSK`s ADC Blenrep delivers survival win against J&J`s Darzalex
14 Nov 2024 //
FIERCE PHARMA
Nipocalimab Shows Significant Improvement in Sjögren’s Study
14 Nov 2024 //
GLOBENEWSWIRE
J&J gets FDA OK to begin trials for its Ottava surgical robot
12 Nov 2024 //
FIERCE BIOTECH
J&J asks US judge to rule drug-rebate program lawful
12 Nov 2024 //
REUTERS
Nipocalimab Receives FDA Therapy Designation for Sjögren`s Disease
11 Nov 2024 //
PR NEWSWIRE
J&J angles Darzalex for first move into early-stage myeloma
09 Nov 2024 //
FIERCE PHARMA
J&J Submits Darzalex Faspro for High-Risk Myeloma Approval
08 Nov 2024 //
GLOBENEWSWIRE
US FDA approves Johnson & Johnson`s device for heart condition
08 Nov 2024 //
REUTERS
Lawyer increase talc ad spending after J&J`s $9 billion settlement
05 Nov 2024 //
REUTERS
Senhwa Biosciences Appoints Dr. Yiu-Lian Fong as New Director
01 Nov 2024 //
PR NEWSWIRE
Tremfya is 1st IL-23 Inhibitor with Subcutaneous in Crohn`s Disease
28 Oct 2024 //
PR NEWSWIRE
Positive results for J&J’s Tremfya in plaque psoriasis
26 Oct 2024 //
PRESS RELEASE
J&J`s Tremya, Lilly`s Ebglyss score in new patient groups
25 Oct 2024 //
FIERCE PHARMA
J&J Showcases Neuropsychiatry Portfolio At Psych Congress
24 Oct 2024 //
PR NEWSWIRE
DARZALEX® Approved for Newly Diagnosed Multiple Myeloma Patients
23 Oct 2024 //
GLOBENEWSWIRE
DOJ files motion to derail J&J`s Texas two-step talc settlement
22 Oct 2024 //
FIERCE PHARMA
J&J’s Tremfya May Set New Standard In Crohn’s Disease
21 Oct 2024 //
FINANCIALXPRESS
Accord Healthcare Receives Positive CHMP Opinion for Imuldosa
19 Oct 2024 //
PR NEWSWIRE
New J&J Tremfya ad puts inclusive twist on psoriasis marketing
16 Oct 2024 //
FIERCE PHARMA
J&J must pay 15M to man who says its talc caused his cancer
16 Oct 2024 //
REUTERS
Cancer drug sales lift J&J past Wall Street expectations
15 Oct 2024 //
REUTERS
Johnson & Johnson Reports Q3 2024 Results
15 Oct 2024 //
BUSINESSWIRE
J&J Announces Quarterly Dividend for Fourth Quarter 2024
15 Oct 2024 //
BUSINESSWIRE
Nipocalimab Demonstrates Disease Control In Myasthenia Gravis Study
15 Oct 2024 //
GLOBENEWSWIRE
Forbion`s €2B funds are largest yet, with 30 biotechs to benefit
15 Oct 2024 //
FIERCE BIOTECH
Lilly reports Ph 3 study of mirikizumab compared to ustekinumab for Crohn
15 Oct 2024 //
PR NEWSWIRE
J&J talc bankruptcy in Texas despite `forum-shopping` opposition
11 Oct 2024 //
REUTERS
Johnson & Johnson to Participate in Stifel 2024 Healthcare Conference
10 Oct 2024 //
BUSINESSWIRE
